Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival

Journal of the National Cancer Institute

Volumn 105, Issue 19, 2013, Pages 1456-1462

  Chubak, Jessica ^a,b   Boudreau, Denise M ^a,b   Wirtz, Heidi S ^a,b   McKnight, Barbara ^b   Weiss, Noel S ^b,c  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONFOUNDING VARIABLE; ELECTRONIC MEDICAL RECORD; EPIDEMIOLOGICAL DATA; FOLLOW UP; HUMAN; HYPOTHESIS; MEDICAL HISTORY; MEDICAL RECORD REVIEW; METHODOLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSTDIAGNOSIS EXPOSURE; PRIORITY JOURNAL; REVERSE CAUSATION; REVIEW; VALIDITY;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE PROGRESSION; EPIDEMIOLOGIC STUDIES; HUMANS; INTERVIEWS AS TOPIC; NEOPLASMS; OBSERVATION; OBSERVER VARIATION; RECURRENCE; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SELECTION BIAS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84885453640     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt211     Document Type: Review

References (34)

1. Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat. 2008;112(1):123-132
2. O?Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93(10):754-762
3. Blair CK, Sweeney C, Anderson KE, Folsom AR. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat. 2007;101(2):191-197
4. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649-658
5. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467-1472
6. Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2007;18(6):613-620
7. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf. 2011;20(2)131-137
8. Csizmadi I, Collet JP, Boivin JF. Bias and confounding in pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons; 2005:791-807
9. Hamer M, Stamatakis E, Saxton J. The impact of physical activity on allcause mortality in men and women after a cancer diagnosis. Cancer Causes Control. 2009;20(2):225-231
10. Rothman KJ. Induction and latent periods. Am J Epidemiol. 1981;114(2):253-259
11. Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011;103(20):1540-1551
12. Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103(19):1461-1468
13. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615-625
14. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561-570
15. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560
16. Chubak J, Yu O, Pocobelli G, et al. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst. 2012;104(12):931-940
17. Hassett MJ, Ritzwoller DP, Taback N, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. [published online ahead of print December 6, 2012]. Med Care. 2012
18. Orgeas CC, Hall P, Wedren S, Dickman PW, Czene K. The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patients. Eur J Cancer. 2009;45(17):3064-3073
19. Cook LS, Weiss NS, Doherty JA, Chen C. Endometrial Cancer. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006:1027-1043
20. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Postdiagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. 2008;109(3):573-579
21. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998
22. Ness KK, Leisenring W, Goodman P, et al. Assessment of selection bias in clinic-based populations of childhood cancer survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2009;52(3):379-386
23. Armstrong BK, White E, Saracci R. Principles in Exposure Measurement In Epidemiology. Vol Oxford: Oxford University Press; 1992
24. Puts M, Monette J, Girre V, et al. Participation of older newly-diagnosed cancer patients in an observational prospective pilot study: an example of recruitment and retention. BMC Cancer. 2009;9(1):277
25. Littman A, Boyko E, Jacobson I, et al. Assessing nonresponse bias at follow-up in a large prospective cohort of relatively young and mobile military service members. BMC Med Res Methodol. 2010;10(1):99
26. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22(3):278-295
27. Hosmer DW Jr, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons; 1999
28. Wolkewitz M, Allignol A, Harbarth S, de Angelis G, Schumacher M, Beyersmann J. Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. J Clin Epidemiol. 2012;65(11):1171-1180
29. Breslow NE, Day NE. Statistical Methods in Cancer Research: Volume II- The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer; 1987
30. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389-2430
31. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-554
32. Tsiatis A. A nonidentifiability aspect of the problem of competing risks. Proc Natl Acad Sci U S A. 1975;72(1):20-22
33. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage iii colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456-3461
34. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492-499